Revenue and Profit - Revenue for Q1 2025 was CNY 170,805,352, a decrease of 22.68% compared to CNY 220,901,649 in the same period last year[4] - Net profit attributable to shareholders was CNY 58,373,966, down 24.32% from CNY 77,130,242 year-on-year[4] - Basic earnings per share decreased by 25.64% to CNY 0.29 from CNY 0.39 in the previous year[6] - Total operating revenue for Q1 2025 was ¥170,805,352, a decrease of 22.7% compared to ¥220,901,649 in Q1 2024[18] - Net profit for Q1 2025 was ¥58,373,966, down 24.2% from ¥77,130,242 in Q1 2024[19] - Operating profit for Q1 2025 was ¥58,308,200, compared to ¥76,696,519 in Q1 2024, reflecting a decline of 24.0%[18] - Basic and diluted earnings per share for Q1 2025 were both ¥0.29, down from ¥0.39 in Q1 2024[19] - Other comprehensive income after tax for Q1 2025 was ¥843,980, significantly lower than ¥10,703,351 in Q1 2024[19] Cash Flow - Operating cash flow increased by 42.52% to CNY 70,177,811 from CNY 49,240,931 in the same period last year[4] - Cash flow from operating activities increased to ¥70,177,811 in Q1 2025, up 42.5% from ¥49,240,931 in Q1 2024[22] - Cash flow from investing activities showed a net outflow of ¥97,041,004 in Q1 2025, compared to a net inflow of ¥132,590,452 in Q1 2024[23] - Cash flow from financing activities resulted in a net outflow of ¥97,463,057 in Q1 2025, compared to a smaller outflow of ¥7,819,456 in Q1 2024[23] - The ending cash and cash equivalents balance for Q1 2025 was ¥181,964,934, down from ¥750,080,016 at the end of Q1 2024[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,115,726,946, a slight decrease of 0.49% from CNY 3,131,185,579 at the end of the previous year[6] - The company's current assets totaled CNY 1,445,028,686.42, down from CNY 1,522,348,721.66 at the end of 2024, indicating a decrease of approximately 5.08%[13][15] - Cash and cash equivalents decreased to CNY 731,501,989.37 from CNY 853,642,354.80, representing a decline of about 14.3%[13][15] - The company's total liabilities decreased to CNY 762,488,777.80 from CNY 837,166,235.48, reflecting a reduction of approximately 8.9%[15] - The company's inventory rose to CNY 197,370,499.01 from CNY 179,550,878.25, indicating an increase of approximately 9.9%[13][15] - The accounts receivable decreased to CNY 79,297,754.72 from CNY 86,360,292.67, a decline of about 8.3%[13][15] - The company reported a significant reduction in short-term borrowings, which fell to CNY 94,794,120.21 from CNY 187,400,276.58, a decrease of approximately 49.5%[15] - The company's long-term investments slightly decreased to CNY 4,978,640.07 from CNY 5,003,440.74, a decline of about 0.5%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,469[10] - Shareholders' equity attributable to shareholders increased by 2.58% to CNY 2,353,238,168 from CNY 2,294,019,344 at the end of the previous year[6] - The equity attributable to shareholders increased to CNY 2,353,238,168.26 from CNY 2,294,019,344.33, marking an increase of about 2.57%[15] - The company has not reported any significant changes in shareholder relationships or participation in financing activities during the reporting period[11][12] Accounts Receivable and Borrowings - Accounts receivable increased by 33.75%, mainly due to an increase in outstanding receivables at the end of the reporting period[8] - Short-term borrowings decreased by 49.42%, attributed to a reduction in pledged bank acceptance bills[8]

寿仙谷（603896）公告，2025年第一季度营收为1.71亿元，同比下降22.68%；净利润为5837.4万元，同 比下降24.32%。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][15] Core Views - The company achieved a revenue of 692 million yuan in 2024, a year-on-year decrease of 11.81%, with a net profit attributable to shareholders of 175 million yuan, down 31.34% [7] - The gross margin for 2024 was 80.72%, a decrease of 2.00 percentage points, while the net margin was 25.26%, down 7.19 percentage points [7] - The company is expected to see growth driven by marketing reforms in provinces outside of Zhejiang, despite short-term sales pressure [7] Financial Performance Summary - Revenue for 2024 was 692 million yuan, with a year-on-year decline of 11.81% [11] - Net profit attributable to shareholders for 2024 was 175 million yuan, down 31.34% [11] - The company forecasts net profits of 208 million yuan, 240 million yuan, and 274 million yuan for 2025, 2026, and 2027 respectively [7][11] - The earnings per share (EPS) are projected to be 1.05 yuan, 1.21 yuan, and 1.38 yuan for 2025, 2026, and 2027 respectively [7][11] Product and Market Analysis - Revenue from Ganoderma lucidum spore powder products decreased by 16.53% to 445 million yuan in 2024 [8] - Revenue from Dendrobium candidum products fell by 11.00% to 113 million yuan [8] - The company plans to enhance its sales model and marketing strategies to expand its market presence outside of Zhejiang [8] Clinical Research and Internationalization - Clinical research on the anti-tumor effects of Ganoderma lucidum spore powder is progressing well, involving 17 top-tier hospitals [9] - The company is collaborating with the Mayo Clinic on research related to cardiovascular disease treatment using its products [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company achieved a revenue of 692 million yuan in 2024, a year-on-year decrease of 11.81%, with a net profit attributable to shareholders of 175 million yuan, down 31.34% [7] - The company is expected to experience growth driven by marketing reforms outside its home province, despite short-term sales pressure [7] - The projected net profits for 2025, 2026, and 2027 are 208 million yuan, 240 million yuan, and 274 million yuan respectively, with corresponding EPS of 1.05 yuan, 1.21 yuan, and 1.38 yuan [7] Financial Performance Summary - In 2024, the gross margin was 80.72%, down 2.00 percentage points, and the net margin was 25.26%, down 7.19 percentage points [7] - The sales expense ratio increased to 43.89%, while the management expense ratio rose to 12.60% [7] - The company’s total revenue is projected to recover to 728 million yuan in 2025, with a growth rate of 5.2% [11] Product and Market Analysis - Revenue from Ganoderma lucidum spore powder products decreased by 16.53% to 445 million yuan, while revenue from Dendrobium candidum products fell by 11.00% to 113 million yuan [8] - The company plans to enhance its sales model and marketing strategies to expand its market presence outside Zhejiang province [8] Clinical Research and Internationalization - Clinical research projects are progressing well, including studies on the anti-tumor effects of Ganoderma lucidum spore powder [9] - The company is collaborating with top medical institutions, such as the Mayo Clinic, to advance the internationalization of its products [9]

证券代码：603896 证券简称：寿仙谷 公告编号：2025-026 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 13 日 14 点 00 分 召开地点：浙江省武义县黄龙三路 12 号会议室 股东大会召开日期：2025年5月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 13 日 至2025 年 5 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时 ...

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-015 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 第四届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江寿仙谷医药股份有限公司（以下简称"公司"）第四届监事会第十六次 会议于 2025 年 4 月 17 日在公司会议室召开，会议通知于 2025 年 4 月 7 日以电 子邮件形式发出，会议应到监事 3 名，实到监事 3 名，公司董事会秘书、证券事 务代表列席了会议。本次会议由监事会主席徐凌艳女士主持，会议的召开符合《公 司法》及《公司章程》的有关规定。 二、监事会会议审议情况 （一）审议并通过《浙江寿仙谷医药股份有限公司监事会 2024 年度工作报 告》 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 本议案尚需提交公司 2024 年年度股东大会审议。 （二）审议并通过《浙 ...

| | | 浙江寿仙谷医药股份有限公司 第四届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江寿仙谷医药股份有限公司（以下简称"公司"）第四届董事会第二十八 次会议于 2025 年 4 月 17 日在公司会议室以现场结合线上会议方式召开，会议通 知于 2025 年 4 月 7 日以电子邮件形式发出，会议应到董事 9 名，实到董事 9 名， 公司监事、高级管理人员、董事会秘书列席了会议。本次会议由董事长李明焱先 生主持，会议的召开符合《公司法》及《公司章程》的有关规定。 二、董事会会议审议情况 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 （四）审议并通过《浙江寿仙谷医药股份有限公司独立董事 2024 年度述职 报告》 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 （一）审议并通过《浙江寿仙谷医药股份有限公司董事会 2024 年度工作报 告》 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 本议案尚需提交公司 2024 年年度股东大 ...

浙江寿仙谷医药股份有限公司 第四届董事会独立董事专门会议 2025年第一次会议决议 浙江寿仙谷医药股份有限公司(以下简称"公司")第四届董事会独立董事 专门会议 2025 年第一次会议于 2025年 4 月 16 目在公司会议室以通讯表决的方 式召开,会议通知于 2025年 4月 7 日以电子邮件形式发出,会议应到独立董事 3 名,实到独立董事 3 名。本次会议的召开符合《上市公司独立董事管理办法》 及《寿仙谷独立董事专门会议工作细则》等有关规定。 本次会议由独立董事韩海敏先生主持,审议并作出如下决议: 1、审议并通过《浙江寿仙谷医药股份有限公司 2025 年度日常关联交易预案》 独立董事认为:公司 2025 年度日常关联交易预案系基于市场环境的变化以 及公司生产经营的实际需求制订,遵循了公平、公正、自愿、诚信的原则,符合 《上海证券交易所上市公司自律监管指引第5号 -- 交易与关联交易》等有关法 律、法规和规范性文件的规定。关联交易定价公允,不存在利益输送的情形,不 存在损害公司或股东利益,特别是非关联股东和中小股东利益的情形;一致同意 将该议案提交公司董事会审议。在公司董事会对该议案进行表决时,关联董事应 ...

| 证券代码：603896 | 证券简称：寿仙谷 | | | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | | | 公告编号：2025-021 | 浙江寿仙谷医药股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股派发现金红利 0.27 元（含税）。 经立信会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于上 市 公 司 股 东 的 净 利 润 174,714,540.37 元 ， 母 公 司 2024 年 度 实 现 净 利 润 203,633,814.12 元，根据公司章程，母公司法定盈余公积累计额为注册资本的百 分之五十以上的可不再提取，母公司 2024 年度实际未提取法定盈余公积，母公 司 2024 年度实际可供股东分配利润为 203,633,814.12 元，截至 2024 年 12 月 31 日，母公司累计可供分配利润为 727,119,064.44 元。 经公 ...